Tetrahydrocannabinol (THC)

Here, we bring you our top four recent articles covering research on cannabis and multiple sclerosis, New York’s Responsible Workforce Training program, veteran use of natural products, and testimony from the US Hemp Roundtable.

Check out the complete series from our Cannabis Analysis column.

Here, Scott Mazza, Founder of Vitality CBD, discusses what science and law say about the cannabinoid THCA.

Here, we discuss how to perform a validation, how to calculate the Standard Error of Prediction, and the best metric of calibration quality.

This article examines what rescheduling cannabis would involve, the implications for various sectors, and the potential roadblocks that could arise along the way.

A Tilray-funded case series found that cannabinoid treatment provided pain relief and improved other symptoms.

Products containing Delta-8 THC may be leading to an increase in calls to poison control centers, according to a recent study.

This article provides an analysis of current regulations and proposed changes that could impact the hemp industry.

California’s bill creating new restrictions on intoxicating hemp products has prompted responses citing negative impacts on patients and businesses.

This month’s webinar discussed studies conducted on cannabis and psychedelics for various conditions including anxiety and autism spectrum disorder.

Here, we discuss the importance of calibration metrics and how to measure calibration quality.

This review highlights an in-silico assessment of the binding interactions of pro-drug moiety analogs and an importance in identifying potential issues that would need further testing to ensure safety for consumers such as the hERG values which are pertinent in the pharmaceutical fields in whether or not drugs can be safe to use.

Here, Scott Mazza, Founder of Vitality CBD, compares the effects of the cannabis compounds CBD and THC for use with various conditions.

This article discusses the early experiments and studies on the effects of two cannabinoids on anxiety.

Here, we will introduce systematic error, discuss how to measure signal-to-noise ratios, and more.

As markets mature, manufacturing terpene blends have become a new art form and a differentiating factor for potential therapeutic applications. Here, we dive deeper into the insights of terpene formulation considerations.

In this blog installment, we take a deep dive into research on how cannabis affects neurodegenerative disorders such as Alzheimer’s disease, multiple sclerosis, and Parkinson’s disease.

Japan is amending a piece of hemp legislation which will help expand rules regarding hemp but would restrict cannabis regulation.

In this article our sister brand, Nutritional Outlook takes a look at delta-8 THC and where regulators could ultimately land in regard to this controversial cannabinoid.

All THC-containing products must be sold exclusively at licensed dispensaries only.

The FDA and FTC have sent warnings to several companies that market delta-8 THC edibles.

The NCAA is reconsidering changing their tune on cannabis and removing the plant from their banded drug list.

A tutorial article that delineates the rising threats of “lab shopping” and THC inflation to the US cannabis industry and proposes solutions to overcome them.

The webinar "Cannabis and Dementia: Unlocking the Potential" was held on June 14, 2023, and featured four panelists’ experiences treating dementia symptoms with cannabis.

Noting the current lack of an accurate cannabis breathalyzer, researchers in a protocol development study analyzed levels of THC before and after participants smoked cannabis.

This article provides insights into the opportunities involving the genetic modification of cannabis.

The current challenges and future perspectives of the purification of cannabinoids from cannabis extracts are presented in this review article.

A test of a small sample of products sold in the Twin Cities revealed amounts of THC past the legal limit.

In this article, we explore how cannabis extraction technology can preserve the acidic cannabinoids in the process.

A civil lawsuit filed in Arkansas by a medical cannabis patient alleges that three cannabis growers and one testing laboratory inflated the amount of tetrahydrocannabinol (THC) in numerous cannabis products.